Genmab — Oktober 2018
-
There is still much uncertainty around Darzalex’s weighty 2024 forecast of $6bn, however; an unexplained price cut earlier this year shook investor confidence, and many analysts will be waiting to see how the drug fares in front-line settings to sharpen their sales predictions.
-
http://www.evaluate.com/vantage/articles/news/snippets/genmab-surges-maia-trial-opens-gates-us
Genmab surges as Maia trial opens gates to the US -
nåja - 906 er da bedre end et spark I nødderne
-
i første omgang bliver det spændende at se hvordan FDA tager imod ansøgningen
-
@E L @nohope. En dårligere median PFS for DRd kan teoretisk godt lade sig gøre, hvis fx enrollment eller censoring har været ujævn mellem de to arme. Det er ikke ligetil at overføre hazard ratio til median PFS, som fx Løntoft ellers har gjort i dag. Man kan dog godt lave nogle estimeringer, men de er med store usikkerheder.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind